On a filed basis, annual revenue moved from KRW 156.7 billion in 2022 to KRW 154.8 billion in 2023 (down 1.2%) and KRW 130.1 billion in 2024 (down 16.0%), before recovering to KRW 168.5 billion in 2025 (up 29.5%). 2025 was the largest year of 2022–2025 and 2024 the smallest.
Operating profit fell from KRW 17.2 billion in 2022 to KRW 1.04 billion in 2023 (down 93.9%), then turned into an operating loss of KRW 30.8 billion in 2024. The 2025 operating loss of KRW 4.53 billion was smaller. Operating losses were recorded in 2024 and 2025, two consecutive loss years.
The operating margin was 11.0% in 2022, 0.7% in 2023, -23.6% in 2024 and -2.7% in 2025.
Attributable net income fell from KRW 12.4 billion in 2022 to KRW 4.67 billion in 2023 (down 62.5%), then became an attributable net loss of KRW 35.1 billion in 2024 and narrowed to an attributable net loss of KRW 3.23 billion in 2025.
Net income including non-controlling interests was a net loss of KRW 3.29 billion in 2025.
The company attributed the 2025 improvement to sales growth in its pharmaceutical business, easing of past drug price cut effects and streamlined costs, while the bio unit said a temporary revenue stall tied to FDA approval preparation ended and commercial project production ramped up (as reported in March 2026).
Quarterly, Q3 2025 operating profit was KRW 242 million, but Q4 2025 swung to an operating loss of KRW 6.34 billion, and press reports linked this to the Songdo plant shutdown.
Revenue bottomed at KRW 35.3 billion in Q1 2026 and then rose to KRW 37.8 billion in Q2 and KRW 51.5 billion in Q3, two consecutive quarters of growth. The operating loss widened to KRW 8.97 billion in Q1 and KRW 9.15 billion in Q2, then Q3 posted operating profit of KRW 1.46 billion, up 501.8% year on year.
The attributable net loss reached KRW 15 billion in Q2 2026 before Q3 attributable net income of KRW 1.45 billion. Attributable net losses over the last four quarters total KRW 26.9 billion. Operating cash flow went from KRW 17.1 billion in 2022 to -KRW 9.43 billion in 2024 and -KRW 23.3 billion in 2025.
The debt ratio rose from 55.2% in 2022 to 66.1% in 2025. At the end of 2025, total equity was KRW 187.5 billion, of which attributable equity was KRW 187.3 billion, and total liabilities were KRW 124 billion.